Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 501.82% and ...

The U.S. Food and Drug Administration (FDA) announced on Monday the approval of the first generic version of a ...

Elon Musk, 53, admitted to taking Mounjaro, a drug that typically treats type-2 diabetes by lowering a person's blood sugar ...

In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...

Amazon may be known for its retail and tech chops, but the company has also built a strong operation in the healthcare realm ...

Her doctor was on board, so long as Hasan also agreed to start resistance training—something she had only done briefly in the ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Lower interest rates boost biotech investments by increasing risk appetite, benefiting pre-commercial biotechs. Read more on how these companies may perform in 2025.

Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...